Amphastar Pharmaceuticals Change in Assets/Liabilities 2012-2024 | AMPH
Amphastar Pharmaceuticals change in assets/liabilities from 2012 to 2024. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
Amphastar Pharmaceuticals Annual Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$-14 |
| 2023 |
$-6 |
| 2022 |
$-5 |
| 2021 |
$0 |
| 2020 |
$-3 |
| 2019 |
$-6 |
| 2018 |
$1 |
| 2017 |
$-5 |
| 2016 |
$1 |
| 2015 |
$-1 |
| 2014 |
$0 |
| 2013 |
$0 |
| 2012 |
$0 |
| 2011 |
$-2 |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.553B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
